Drug Profile

VS 041

Alternative Names: VS-041

Latest Information Update: 12 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vasa Therapeutics
Class Antifibrotics; Heart failure therapies; Small molecules
Mechanism of Action Matrix metalloproteinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Heart failure

Most Recent Events

04 Jun 2025 Safety and pharmacokinetics data from a phase I trial in Heart failure released by Vasa Therapeutics
04 Jun 2025 Safety data from preclinical trials in Heart failure released by Vasa Therapeutics
04 Jun 2025 Vasa Therapeutics completes a first-in-human phase I trial in Heart failure (In volunteers) in United Kingdom (PO, Tablet)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com